Sage Advises Solasia on a Global Partnership for Darinaparsin, a Novel Treatment for Peripheral T Ce
Solasia has engaged The Sage Group to manage a program to establish a global partnership regarding licensing of its Darinaparsin product in USA and Europe.
Darinaparsin or SP-02 is a new product from Solasia for the treatment of Peripheral T-Cell Lymphoma (PTCL). Solasia is working with Sage Group to license SP-02 in USA and Europe where they own all rights.
Solasia Pharma (“Solasia” or the “Company”; www.solasia.co.jp) is a privately owned company based in Japan. It is headquartered in Tokyo, with a subsidiary in Shanghai and offices in Beijing. Solasia has a strong and experienced management team from Amgen, Searle, Roche, Takeda and Sosei.
Solasia is a specialty pharmaceutical company established to develop and commercialize innovative oncology therapies and supportive care products in Japan and Asian countries.
Solasia targets the world’s largest oncology market in China and Japan, and has in-licensed three western oncology compounds acquired for Asia markets. These include Darinaparsin (SP-02) from Ziopharm Oncology. Darinaparsin has already been licensed for Japan and Asia to Meiji Seika. Darinaparsin is a water soluble organic arsenic derivative which has been shown to be safe and efficacious in treatment of Peripheral T Cell Lymphoma, where there is a large market due to unmet clinical need. The Company has Orphan Drug designation in USA and EU.
Solasia owns global rights to Darinaparsin, and because it is focused on Asian markets, it would like to identify and negotiate one or more relationships in USA and Europe to market the product also in those territories.